AR045081A1 - Modificaciones estables de maleato de hidrogeno de tegaserod - Google Patents

Modificaciones estables de maleato de hidrogeno de tegaserod

Info

Publication number
AR045081A1
AR045081A1 ARP040102610A ARP040102610A AR045081A1 AR 045081 A1 AR045081 A1 AR 045081A1 AR P040102610 A ARP040102610 A AR P040102610A AR P040102610 A ARP040102610 A AR P040102610A AR 045081 A1 AR045081 A1 AR 045081A1
Authority
AR
Argentina
Prior art keywords
angtron
hydrogen maleate
tegaserod hydrogen
crystal
tegaserod
Prior art date
Application number
ARP040102610A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34135099&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR045081(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR045081A1 publication Critical patent/AR045081A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Glass Compositions (AREA)
  • Liquid Crystal Substances (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente se refiere a formas de maleato de hidrógeno de tegaserod, su uso en composiciones farmacéuticas útiles en el tratamiento del síndrome de intestino irritable, padecimiento de reflujo gastro-esofagal, dispepsia funcional, constipación crónica o diarrea y su producción. Reivindicación 2: Una modificación de cristal A de maleato de hidrógeno de tegaserod, comprendiendo la siguiente estructura de cristal características, determinada por medio de un análisis único de cristal de rayos X: Sistema de cristal es triclinica; Grupo de espacio es P-1; a, Angtron es 8.640; b, Angtron es 15.800; c, Angtron es 17.572; alfa, Angtron es 68.67; beta, Angtron es 88.10; gama, Angtron es 88.02; V, Angtron3 es 2232; Z es 4; D(calc) g /cm3 es 1.242.
ARP040102610A 2003-07-24 2004-07-22 Modificaciones estables de maleato de hidrogeno de tegaserod AR045081A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US48963803P 2003-07-24 2003-07-24

Publications (1)

Publication Number Publication Date
AR045081A1 true AR045081A1 (es) 2005-10-12

Family

ID=34135099

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040102610A AR045081A1 (es) 2003-07-24 2004-07-22 Modificaciones estables de maleato de hidrogeno de tegaserod

Country Status (24)

Country Link
US (1) US20070112056A1 (es)
EP (2) EP1880992A1 (es)
JP (1) JP2006528609A (es)
KR (1) KR20060040710A (es)
CN (1) CN1826318A (es)
AR (1) AR045081A1 (es)
AU (1) AU2004263285A1 (es)
BR (1) BRPI0412830A (es)
CA (1) CA2532351A1 (es)
CO (1) CO5680418A2 (es)
EC (1) ECSP066306A (es)
IL (1) IL172914A0 (es)
IS (1) IS8321A (es)
MA (1) MA27935A1 (es)
MX (1) MXPA06000917A (es)
MY (1) MY137386A (es)
NO (1) NO20060915L (es)
NZ (1) NZ544596A (es)
PE (1) PE20050253A1 (es)
RU (1) RU2349585C2 (es)
SG (1) SG144944A1 (es)
TN (1) TNSN06024A1 (es)
TW (1) TW200510302A (es)
WO (1) WO2005014544A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006045120A2 (en) * 2004-10-19 2006-04-27 Teva Pharmaceutical Industries Ltd. Purification of tegaserod maleate
JP2008528615A (ja) * 2005-01-31 2008-07-31 ノバルティス アクチエンゲゼルシャフト プロトンポンプ阻害剤により誘発され得る遅延した胃内容排出の処置のための５−ｈｔ４アゴニストの使用
CZ298399B6 (cs) * 2005-05-02 2007-09-19 Zentiva, A. S. Zpusob prípravy 2-[(5-methoxy-1 H-indol-3-yl) methylen]-N-pentylkarbazimidamidu (tegaserodu)
US20070112057A1 (en) * 2005-06-22 2007-05-17 Santiago Ini Polymorphic forms of tegaserod maleate
WO2007119109A2 (en) * 2005-10-06 2007-10-25 Medichem, S.A. Processes for preparing tegaserod maleate and pharmaceutical compositions containing it
GB0524668D0 (en) * 2005-12-02 2006-01-11 Novartis Ag Organic compounds
WO2007120924A1 (en) * 2006-04-17 2007-10-25 Teva Pharmaceutical Industries Ltd. Preparation of tegaserod maleate free of iodide
EP1956002A1 (en) * 2007-02-07 2008-08-13 Chemo Ibérica, S.A. New tegaserod maleate polymorphs and process for their preparation
AU2008252604A1 (en) * 2007-05-17 2008-11-27 Generics [Uk] Limited Process for the preparation of form A of tegaserod

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01242588A (ja) * 1988-03-25 1989-09-27 Chiba Gosei Kenkyusho:Kk ７―シアノメチルチオアセトアミド―７α―メトキシ―３―（１―メチル―１Ｈ―テトラゾール―５―イル）チオメチル―３―セフェム―４―カルボン酸の結晶及びその製造方法
HUT64023A (en) * 1991-03-22 1993-11-29 Sandoz Ag Process for producing aminoguanidine derivatives and pharmaceutical compositions comprising such compounds
JPH08291140A (ja) * 1995-04-20 1996-11-05 Teikoku Chem Ind Corp Ltd 易吸収性結晶
RS50104B (sr) * 1998-08-21 2009-01-22 Novartis Ag., Nova oralna formulacija za 5-th4 agoniste ili antagoniste
EP1321142A1 (en) * 2001-12-21 2003-06-25 Novartis AG Solid pharmaceutical composition for oral administration of Tegaserod
CN1176077C (zh) * 2003-01-07 2004-11-17 江苏省药物研究所 马来酸替加色罗一水结晶
AU2003222439A1 (en) * 2003-03-25 2004-10-18 Hetero Drugs Limited Novel crystalline forms of tegaserod maleate
WO2005058819A2 (en) * 2003-12-16 2005-06-30 Teva Pharmaceutical Industries Ltd. Polymorphic forms of tegaserod base and salts thereof
US20050272802A1 (en) * 2004-04-22 2005-12-08 Sundaram Venkataraman Process for preparing form I of tegaserod maleate
US20070112057A1 (en) * 2005-06-22 2007-05-17 Santiago Ini Polymorphic forms of tegaserod maleate

Also Published As

Publication number Publication date
MA27935A1 (fr) 2006-06-01
IL172914A0 (en) 2006-06-11
PE20050253A1 (es) 2005-06-03
CO5680418A2 (es) 2006-09-29
TW200510302A (en) 2005-03-16
EP1651601A1 (en) 2006-05-03
TNSN06024A1 (en) 2007-10-03
IS8321A (is) 2006-02-22
MXPA06000917A (es) 2006-03-30
AU2004263285A1 (en) 2005-02-17
ECSP066306A (es) 2006-07-28
CA2532351A1 (en) 2005-02-17
NO20060915L (no) 2006-04-24
US20070112056A1 (en) 2007-05-17
NZ544596A (en) 2009-01-31
RU2349585C2 (ru) 2009-03-20
MY137386A (en) 2009-01-30
KR20060040710A (ko) 2006-05-10
JP2006528609A (ja) 2006-12-21
EP1880992A1 (en) 2008-01-23
BRPI0412830A (pt) 2006-09-26
WO2005014544A1 (en) 2005-02-17
CN1826318A (zh) 2006-08-30
SG144944A1 (en) 2008-08-28
RU2006105481A (ru) 2007-09-20

Similar Documents

Publication Publication Date Title
ECSP066306A (es) Modificaciones estables de maleato ácido de tegaserod
CL2004000778A1 (es) Compuestos derivados de heterociclos de 5 miembros, inhibidores de la porteina tirosina fosfatasa 1b (ptp1b); composiciones farmaceuticas, utiles para tratar hipertension, obesidad, diabetes, hiperlipidemia.
EA200870465A1 (ru) Антагонисты рецептора il-8
AR052744A1 (es) Composiciones que comprenden componentes probioticos y edulcorantes
AR058871A1 (es) Uso de una composicion inmunogenica de pcv2 para reducir los sintomas clinicos en cerdos
AR058648A1 (es) Sistema abrasivo para composiciones de cuidado oral
RU2010102067A (ru) Комбинированные композиции, включающие дарунавир и этравирин
CL2003002678A1 (es) Compuestos derivados de piperidina, moduladores de la actividad del receptor ccr5; procedimiento de preparacion; composicion farmaceutica, y su uso en el tratamiento de enfermedades inmunologicas, inflamatorias, asma, artritis reumatoidea y ateroescl
ATE515494T1 (de) Neue verbindungen, deren herstellung und verwendung
NO20033959D0 (no) Benzimidazoler som er nyttige i behandling av seksuell dysfunksjon
WO2001068568A3 (en) Il-8 receptor antagonists
ATE330581T1 (de) Silylierte verbindungen als vorläufer für selbstbräunungs zusammensetzngen
CL2008003182A1 (es) Compuestos derivados de 1,2,4-triazol-3-amino; composicion farmaceutica; y su uso en el tratamiento del dolor, reflujo gastroesofagico, ansiedad, sindrome del intestino irritable.
AP1548A (en) Il-8 Receptor Antagonists.
RU2007122891A (ru) Средство для увеличения выхода биогаза
MX2007014297A (es) Derivados de purina y su uso para el tratamiento de enfermedades autoinmunes.
DE602005024539D1 (de) Neue verbindungen, ihre herstellung und verwendung
ATE469882T1 (de) Neue verbindungen, die sich f r die behandlung von durch ppar vermittelten krankheiten eignen
MY143477A (en) Il-8 receptor antagonists
CY1108048T1 (el) Συνθεση σπογγοσινης
RU2007125000A (ru) Керамическая масса
WO2001068033A3 (en) Il-8 receptor antagonists
TR200103690T2 (tr) IL-8 reseptör antagonistleri
ECSP003527A (es) Antagonistas del receptor de il - 8 v
张振宇 et al. Study on Microstructure and Nanomechanics Properties of Antibacterial Bone China

Legal Events

Date Code Title Description
FA Abandonment or withdrawal